Tiny biotech takes on Glaxo’s $730000 gene therapy – SFGate
|
Tiny biotech takes on Glaxo’s $730000 gene therapy
SFGate GlaxoSmithKline has seen precious few takers for its $730,000 gene therapy for a rare and life-threatening immune illness known as “bubble-boy disease.” Now a tiny startup thinks it can succeed where the British giant is struggling. In almost two years … |
NOLA.com |
This Lusher junior’s stem cell research is sending her to an international science fair
NOLA.com A junior from Lusher Charter School in Uptown was awarded first place in Cell and Molecular Biology at the Greater New Orleans Science and Engineering Fair, where more than 350 middle and high school students from the metropolitan area displayed the … |
|
Roswell Park Approved to Administer CAR T-Cell Therapy, Yescarta, to Lymphoma Patients
Newswise (press release) Newswise — BUFFALO, N.Y. — Roswell Park Comprehensive Cancer Center has been officially approved to administer an FDA-approved CAR T-cell therapy, Yescarta, to lymphoma patients. It’s manufactured by Kite, a Gilead Company. Yescarta, also known as … |
Buffalo Business First |
Roswell Park Approved to Administer CAR T-Cell Therapy, Yescarta, to Lymphoma Patients
Newswise (press release) Newswise — BUFFALO, N.Y. — Roswell Park Comprehensive Cancer Center has been officially approved to administer an FDA-approved CAR T-cell therapy, Yescarta, to lymphoma patients. It’s manufactured by Kite, a Gilead Company. Yescarta, also known as … Roswell Park to offer new lymphoma immunotherapyBuffalo Business First |